Efficacy of Atomoxetine in Children With Severe Autistic Disorders and Symptoms of ADHD: An Open-Label Study
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study aims to examine the efficacy of atomoxetine in treating symptoms of attention deficit hyperactivity disorder (ADHD) in children with severe autistic disorder. METHOD: Children with severe autistic disorder who had symptoms of ADHD were given atomoxetine for 10 weeks. The efficacy of atomoxetine was evaluated by using the Aberrant Behavior Checklist (ABC) to rate ADHD symptoms at baseline, week 6, and week 10. The Clinical Global Impression-Improvement (CGI-I) scale was used as secondary outcome to assess the overall improvement of the children's development at week 10. RESULTS: A total of 12 children participated in this study. Although CGI-I scores showed improvement at week 10, the ABC hyperactivity subscale did not show a significant improvement of the ADHD symptoms at baseline (M = 33.89) compared to those at week 10 (M = 31.78, p = .62). CONCLUSION: Atomoxetine did not benefit children with severe autistic disorder who have ADHD symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a separate investigation, atomoxetine treatment yielded no observed symptom reduction in a sample of children with high ASD symptom severity [46].”
From Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder (2012) · cites this paper as [46]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Diagnostic and Statistical Manual of Mental Disorder
Ellsworth, P. D. (1980) · The American Journal of Occupational Therapy · doi:10.5014/ajot.34.12.819a · Cited by 1,700
(1985) · PubMed · Cited by 1,427
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 2×
“…could be a potential alternative treatment for attention deficit and hyperactive symptoms with tolerable adverse effects (Biederman et al., Atomoxetine ADHD Study Group, 2002; Buitelaar et al., 2004; Cheng, Chen, Ko, & Ng, 2007; Escobar et al., 2005; Kelsey et al., 2004; Michelson et al., 2002).”
BackgroundLecavalier, L. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0147-5 · Cited by 569 · cited 1×
“Lecavalier (2006) found that children with PPD displayed behavior and emotional problems including symptoms associated with attention deficit and hyperactivity.”
Background(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 2×
“…could be a potential alternative treatment for attention deficit and hyperactive symptoms with tolerable adverse effects (Biederman et al., Atomoxetine ADHD Study Group, 2002; Buitelaar et al., 2004; Cheng, Chen, Ko, & Ng, 2007; Escobar et al., 2005; Kelsey et al., 2004; Michelson et al., 2002).”
BackgroundGoldstein, S., & Schwebach, A. J. (2004) · Journal of Autism and Developmental Disorders · doi:10.1023/b:jadd.0000029554.46570.68 · Cited by 412 · cited 1×
“Children with PDD who exhibited attention deficit and hyperactive symptoms were found to have greater difficulty in daily activities than children with PDD without attention deficit and hyperactive symptoms (Goldstein & Schwebach, 2004).”
BackgroundHanden, B. L., Johnson, C. R., & Lubetsky, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005548619694 · Cited by 326
Research works printed but not linked: 3
- Aman M. G., 1985, American Journal of Mental Deficiency, 89, 485
- Arnold L. E., 2006, Journal of the American Academy of Child and Adolescent Psychiatry, 45, 10
- Escobar R., 2005, Actas Españolas de Psiquiatría, 33, 26
Cited by
Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder
Davis, N. O., & Kollins, S. H. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0126-9 · Cited by 156
Psychopharmacological interventions in autism spectrum disorder
Accordino, R. E., Kidd, C., Politte, L. C., Henry, C. A., & McDougle, C. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1154536 · Cited by 126
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“At least six studies indicate that atomoxetine may be an effective treatment for ADHD symptoms in patients with co-morbid pervasive developmental disorders [138, 155– 160], although five of these studies are small (B16 patients), with treatment durations up to 10 weeks [138, 157–160].”
BackgroundBushe, C. J., & Savill, N. C. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113478475 · Cited by 72
Vahabzadeh, A. B. N., Keshav, N. U., Salisbury, J. P., & Sahin, N. T. (2018) · JMIR Mental Health · doi:10.2196/mental.9631 · Cited by 80
Psychopharmacological Interventions in Autism Spectrum Disorder
Politte, L. C., Henry, C. A., & McDougle, C. J. (2014) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000030 · Cited by 71
Pharmacotherapy of autism spectrum disorders
Benvenuto, A., Battan, B., Porfirio, M. C., & Curatolo, P. (2012) · Brain and Development · doi:10.1016/j.braindev.2012.03.015 · Cited by 72
Clemow, D., Bushe, C., Mancini, M., Ossipov, M., & Upadhyaya, H. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s115707 · Cited by 58
Savill, N. C., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., & Coghill, D. (2015) · CNS Drugs · doi:10.1007/s40263-014-0224-9 · Cited by 66
Evidence-Based Treatments for Autism Spectrum Disorder
Politte, L. C., Howe, Y. J., Nowinski, L. A., Palumbo, M., & McDougle, C. J. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0031-z · Cited by 57
A review of atomoxetine effects in young people with developmental disabilities
Aman, M. G., Smith, T. H., Arnold, L. E., Corbett-Dick, P., Tumuluru, R. V., Hollway, J. A., Hyman, S. L., Mendoza-Burcham, M., Pan, X. J., Mruzek, D. W., et al. (2014) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2014.03.006 · Cited by 57
Hutchison, S. L., Ghuman, J. K., Ghuman, H. S., Karpov, I., & Schuster, J. M. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316647686 · Cited by 41
Bertelli, M. O., Azeem, M. W., Underwood, L., Scattoni, M. L., Persico, A. M., Ricciardello, A., Sappok, T., Bergmann, T. J., Keller, R., Bianco, A., et al. (2022) · Springer eBooks · doi:10.1007/978-3-319-95720-3_16 · Cited by 48
Medical Therapies for Children With Autism Spectrum Disorder—An Update
Edwin Williamson, M. D., Sathe, N. A., & Andrews, J. C. (2017) · doi:10.23970/ahrqepccer189 · Cited by 50
Patra, S., Nebhinani, N., Viswanathan, A., & Kirubakaran, R. (2019) · Autism Research · doi:10.1002/aur.2059 · Cited by 46
Atomoxetine for Treating ADHD Symptoms in Autism: A Systematic Review
Ghanizadeh, A. (2013) · Journal of Attention Disorders · doi:10.1177/1087054712443154 · Cited by 43
“Although, some uncontrolled studies suggested its efficacy, it was not shown in another uncontrolled study (Charnsil, 2011).”
BackgroundResultInfluentialInattention and hyperactivity in association with autism spectrum disorders in the CHARGE study
Lyall, K., Schweitzer, J. B., Schmidt, R. J., Hertz-Picciotto, I., & Solomon, M. (2017) · Research in Autism Spectrum Disorders · doi:10.1016/j.rasd.2016.11.011 · Cited by 42
“However, the ABC was designed to measure behavioral deficits in this age group, and the hyperactivity subscale has been used in previous work as a measure of ADHD symptoms in ASD (Arnold et al. 2006; Troost et al. 2006; Charnsil 2011).”
MethodTsujii, N., Usami, M., Naya, N., Tsuji, T., Mishima, H., Horie, J., Fujiwara, M., & Iida, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00249-0 · Cited by 44
Zeiner, P., Gjevik, E., & Weidle, B. (2011) · Acta Paediatrica · doi:10.1111/j.1651-2227.2011.02263.x · Cited by 36
What’s in the pipeline? Drugs in development for autism spectrum disorder
Sung, M., Chin, C. H., Lim, C. G., Liew, A., Lim, C. S., Kashala-Abotnes, E., & Weng, S. J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s39516 · Cited by 26
Kılınçaslan, A., Mutluer, T., Pasabeyoglu, B., Tutkunkardaş, M. D., & Mukaddes, N. M. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0179 · Cited by 19
Friedman, N. D. B., Politte, L. C., Nowinski, L. A., & McDougle, C. J. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch44 · Cited by 17
Clinical Approach in Autism: Management and Treatment
Riesgo, R. D. S., Gottfried, C., & Becker, M. M. (2013) · InTech eBooks · doi:10.5772/54784 · Cited by 15
Eslamzadeh, M., Hebrani, P., Behdani, F., Moghadam, M. D., Panaghi, L., Mirzadeh, M., & Arabgol, F. (2018) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs.10596 · Cited by 14
Beherec, L., Quilici, G., Rosier, A., Gérardin, P., Campion, D., & Guillin, O. (2013) · L Encéphale · doi:10.1016/j.encep.2012.01.014 · Cited by 13
Harfterkamp, M., van der Meer, D., van de Loo-Neus, G. H. H., Buitelaar, J. K., Minderaa, R. B., & Hoekstra, P. J. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0142 · Cited by 12
Neurodevelopmental Disorders: Autism Spectrum Disorder
Thom, R. P., Friedman, N. D. B., Nasir, R. H., Politte, L. C., Nowinski, L. A., & McDougle, C. J. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_36-1 · Cited by 10
Neurodevelopmental Disorders: Autism Spectrum Disorder
Thom, R. P., Friedman, N. D. B., Nasir, R. H., Politte, L. C., Nowinski, L. A., & McDougle, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_36 · Cited by 9
Attention Deficit/Hyperactivity Disorder
Ghanizadeh, A. J. (2021) · Springer eBooks · doi:10.1007/978-3-319-91280-6_1829 · Cited by 7
Pharmacological Intervention for Disruptive Behaviors in Intellectual and Developmental Disabilities
Farmer, C., & Aman, M. G. (2013) · International review of research in developmental disabilities · doi:10.1016/b978-0-12-401662-0.00009-9 · Cited by 6
Yamamuro, K., Tsujii, N., Ota, T., Kishimoto, T., & Iida, J. (2017) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12523 · Cited by 5
Psychotropic Treatment of Autism
Pallanti, S., Bencini, L., Cantisani, A., & Hollander, E. (2015) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000363614 · Cited by 5
Autismo y trastorno por déficit de atención/hiperactividad: intervención farmacológica
Fernández‐Jaén, A., Fernández-Mayoralas, D. M., Perrone, A. L. F., Pérez, B. C., Jareño, N. M., & Arribas, S. L. (2013) · Revista de Neurología · doi:10.33588/rn.57s01.2013285 · Cited by 4
Vahabzadeh, A. B. N., Keshav, N. U., Salisbury, J. P., & Sahin, N. T. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/165514 · Cited by 4
Gupta, N., Boyes, D., Hanlon, H., & Gupta, M. (2025) · JCPP Advances · doi:10.1002/jcv2.70022 · Cited by 1
What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism?
Guest, P. C., & Martins‐de‐Souza, D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_3 · Cited by 1
Uğur, Ç., Uygun, S. D., Üneri, Ö. Ş., Göker, Z., & Çetinkaya, M. (2016) · International Journal of Clinical Pediatrics · doi:10.14740/ijcp237w · Cited by 1
van der Meer, J. M. J. (2014) · Radboud Repository (Radboud University)
Metadata
- Authors
- Charnsil, C.
- Affiliations
- Chiang Mai University (TH)
- Corresponding author
- Charnsil, Chawanun
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2010-08-04
- Volume
- 15
- Issue
- 8
- Pages
- 684-689
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2051954276
- Cited by
- 36
- References
- 25
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 5 · 2014: 4 · 2013: 5 · 2012: 3
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Attention Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, autism spectrum disorder, severe autism, children, ADHD symptoms, hyperactivity, Aberrant Behavior Checklist, CGI-I
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Autistic Disorder, Child, Female, Humans, Male, Pilot Projects, Propylamines, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.